PMV Pharmaceuticals (PMVP) Accounts Payables (2019 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Accounts Payables came in at $1.6 million in Q1 2026, down 54.61% YoY from $3.6 million in Q1 2025, and down 48.3% on a QoQ basis from $3.2 million in Q4 2025.
PMV Pharmaceuticals (PMVP) Accounts Payables (2019 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 8 years of Accounts Payables data on file, last reported at $1.6 million in Q1 2026.
- Quarterly Accounts Payables fell 54.61% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 54.61% YoY) and the FY2025 annual result came in at $3.2 million, down 52.04% from the prior year.
- Accounts Payables eased to $1.6 million in Q1 2026, from $3.2 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $6.6 million in Q4 2024 to a low of $859000.0 in Q1 2024.
- A 5-year average of $3.2 million and a median of $3.2 million in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables sank 65.23% — and 2025, when it jumped 318.28%.
- Tracing PMVP's Accounts Payables over 5 years: stood at $3.0 million in 2022, then increased by 8.04% to $3.2 million in 2023, then surged by 103.24% to $6.6 million in 2024, then plunged by 52.04% to $3.2 million in 2025, then tumbled by 48.3% to $1.6 million in 2026.
- The last three Accounts Payables figures came in at $1.6 million (Q1 2026), $3.2 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | PMV Pharmaceuticals | 70.74 Mn | -8.69 Mn | - | 2.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.63 Mn |
| Dec 31, 2025 | 3.16 Mn |
| Sep 30, 2025 | 3.40 Mn |
| Jun 30, 2025 | 2.60 Mn |
| Mar 31, 2025 | 3.59 Mn |
| Dec 31, 2024 | 6.58 Mn |
| Sep 30, 2024 | 2.06 Mn |
| Jun 30, 2024 | 4.53 Mn |
| Mar 31, 2024 | 859,000.00 |
| Dec 31, 2023 | 3.24 Mn |
| Sep 30, 2023 | 1.68 Mn |
| Jun 30, 2023 | 3.49 Mn |
| Mar 31, 2023 | 1.77 Mn |
| Dec 31, 2022 | 3.00 Mn |
| Sep 30, 2022 | 4.83 Mn |
| Jun 30, 2022 | 3.35 Mn |
| Mar 31, 2022 | 4.86 Mn |
| Dec 31, 2021 | 3.19 Mn |
| Sep 30, 2021 | 1.28 Mn |
| Jun 30, 2021 | 2.37 Mn |